U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Deva Holding AS - 577493 - Cerkezkoy Subesi
  1. Warning Letters

CLOSEOUT LETTER

Deva Holding AS - Cerkezkoy Subesi MARCS-CMS 577493 —

Reference #:
320-19-33
Product:
Drugs
Recipient:
Recipient Name
Ms. Refiye Adiyaman
Recipient Title
Manager, Quality Operations Group
Deva Holding AS - Cerkezkoy Subesi

Halkalı Merkez Mah. Basın Expres Caddesi No:1
34303 Küçükçekmece/İstanbul
Turkey

Issuing Office:
Center for Drug Evaluation and Research | CDER

United States

Dear Ms. Adiyaman,

The Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our Warning Letter 320-19-33 dated August 6, 2019.

Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority.

The FDA expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations and/or deviations be observed during a subsequent inspection or through other means.


Sincerely,
/S/
for Joan Johnson
Compliance Officer
Division of Drug Quality I

Back to Top